DarioHealth's (NASDAQ:DRIO) diabetes managed care platform covers all facets of the disease, with a blood glucose device coupled directly to a patient's smartphone to provide 100% data-capturing, real-time insights, personalized health guidance and professional coaching.
Closely-held liberDi plans to initiate in the first half of 2018 the first-in-man clinical trial of its Smart Peritoneal Dialysis System, a small, portable and automatic dialysis device, which is designed to improve patient's quality of life, and reduce treatment costs and complications.
Closely-held Scientus Pharma hopes to go public in mid-year, possibly through a reverse takeover of a publicly traded shell company, following a successful $15.8-million private equity financing, which closed last week.
3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) has reported positive results from a preliminary analysis of trial data for Telo-HL, its test for Hodgkin's lymphoma (HL) that is designed to personalize treatment for newly diagnosed patients.
IntelGenx (OTCQX:IGXT; TSXV:IGX), which has initiated a proof-of-concept study with its Montelukast VersaFilm in patients with Alzheimer's disease, using a drug originally approved in 1997 for the treatment of asthma, is riding strong scientific rationale behind the repurposing program.
Despite a failed Phase 2 trial in pulmonary arterial hypertension (PAH), Eiger BioPharmaceuticals (NASDAQ:EIGR) still has multiple shots on goal with its targeted therapies for orphan diseases, including a number of key milestones in 2018.
Closely-held Spartan Bioscience’s recently launched an on-site rapid DNA test for Legionnaires’ disease that has the potential to eliminate lengthy culture testing in third-party labs and detect the Legionella bacteria ahead of an outbreak of the disease.